Paladin Labs Inc. announced the launch of Twinject Twinpack in Canada for Anaphylaxis.
Twinject Twinpack includes two Twinject epinephrine auto-injectors and also Twinject demonstrator. Twinject epinephrine auto-injectors allow patients to store an auto-injector in multiple key locations such as home or work, while carrying another device with them at all times. The Twinject demonstrator assist patients and family members in using the auto-injector so they feel more confident in an emergency anaphylactic situation.
It’s vital for individuals at risk for anaphylaxis to be prepared for an emergency, says Laurie Harada, Executive Director, Anaphylaxis Canada. This requires having an auto-injector with them at all times and making sure they and others, such as friends, family members, and caregivers, are comfortable using the device. The demonstrator provides an important hands-on teaching tool.
A recent survey showed that 39 percent to 50 percent of food-induced anaphylactic reactions in children occur outside the home.
We are excited to launch the Twinject Twinpack as it addresses the needs of anaphylactic patients. As such, the Twinject Twinpack will provide superior protection for patients and ensure that they are adequately trained and prepared in an anaphylactic situation, said Mark Beaudet, Vice President Sales and Marketing of Paladin Labs.
Twinject is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). It is available in 0.3 mg and 0.15 mg dosages for self-administration.